Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$8K-9.654,172 shs24,050 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
▼
$0.00
$2K1.347,613 shs35 shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$7K-0.325,637 shs10 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%-60.00%-75.00%-95.56%-99.43%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%-50.00%0.00%0.00%-80.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%-20.00%+33.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$8K-9.654,172 shs24,050 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
▼
$0.00
$2K1.347,613 shs35 shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$7K-0.325,637 shs10 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%-60.00%-75.00%-95.56%-99.43%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%-50.00%0.00%0.00%-80.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%-20.00%+33.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00
N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53M-$0.66N/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/AN/AN/AN/AN/AN/AN/A12/2/2026 (Estimated)

Latest EVLO, CARM, SCPS, and GNCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/17/2026N/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$10.1333N/AN/AN/AN/AN/A
11/5/2026N/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$0.1237N/AN/AN/A$4.66 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
4641.85 million38.91 millionNo Data
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
6618.84 million18.79 millionNo Data
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
918.09 million39.94 millionNot Optionable

Recent News About These Companies

Scopus BioPharma's Subsidiary - Duet BioTherapeutics - Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for ...
June 25, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2023/11/07/scopus-biopharma-s-subsidiary-duet-biotherapeutics-presents-compelling-new-data
Scopus Stock Price History
June 10, 2026  |  investing.comhttps://www.investing.com/equities/scopus-biopharma-inc-historical-data
SCPS Scopus BioPharma Inc.
May 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/SCPS
Scopus Stock Price History - Investing.com
June 29, 2025  |  investing.comhttps://www.investing.com/equities/scopus-biopharma-inc-historical-data?_pmch=1701365167553
Scopus Biopharma Inc (SCPS) Stock Forums - Investing.com
June 29, 2025  |  investing.comhttps://www.investing.com/equities/scopus-biopharma-inc-commentary
Scopus Biopharma Inc Price / Book
November 26, 2024  |  investing.comhttps://www.investing.com/pro/OTCPK:SCPS/explorer/price_to_book
Scopus BioPharma (OTC:SCPS) Stock, Short Interest Report
October 8, 2024  |  benzinga.comhttps://www.benzinga.com/quote/SCPS/short-interest
Scopus Biopharma Inc (SCPS)
February 14, 2024  |  uk.investing.comhttps://uk.investing.com/equities/scopus-biopharma-inc
ArriVent BioPharma Inc AVBP
February 6, 2024  |  morningstar.comM
Scopus BioPharma Inc. (SCPS)
January 31, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SCPS/history/
7+ Companies That Had Their IPO in 2020: Best and Worst Performers
January 8, 2024  |  msn.comhttps://www.msn.com/en-us/money/markets/7-companies-that-had-their-ipo-in-2020-best-and-worst-performers/ss-AA1mylo0
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 7, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/scopus-biopharma-subsidiary-duet-biotherapeutics-141500851.html?.tsrc=rss
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
November 2, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/scopus-biopharma-subsidiary-duet-biotherapeutics-131500358.html
Kinnate Biopharma Inc Ordinary Shares
July 15, 2023  |  morningstar.comM
This Biopharma Offspring Is All Grown Up
May 23, 2023  |  mddionline.comM
Scopus BioPharma Stock (OTC:SCPS), Insider Trading Activity
May 16, 2023  |  benzinga.comhttps://www.benzinga.com/quote/SCPS/insider-trades
ESG Industry Landscape Report: Biopharma
April 19, 2023  |  morningstar.comM
These are the roles biopharma companies want to fill
April 9, 2023  |  siliconrepublic.comS
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
March 18, 2023  |  benzinga.comhttps://www.benzinga.com/pressreleases/23/03/n31388860/ys-biopharma-to-ring-the-opening-bell-and-debut-on-nasdaq
Short Volatility Alert: Scopus Biopharma I
December 16, 2022  |  benzinga.comhttps://www.benzinga.com/markets/penny-stocks/22/12/30112384/short-volatility-alert-scopus-biopharma-i

New MarketBeat Followers Over Time

Top Headlines

View All Headlines
Illuminated Nike swoosh logo on a wall above a display pedestal with sneakers in a retail store.
Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?
By Thomas Hughes | October 4, 2026
Rows of used vehicles parked in a lot outside a CarMax dealership building with its logo displayed.
CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
By Thomas Hughes | September 29, 2026
A candlestick stock price chart overlaid on a blurred urban skyline at dusk.
MarketBeat Week in Review – 09/28 - 10/02
By MarketBeat Staff | October 3, 2026
Split image showing a Carnival cruise ship at sea alongside a CarMax dealership lot with used cars displayed.
Carnival and CarMax Pop on Strong Earnings, but Challenges Remain
By Jessica Mitacek | October 3, 2026
Exterior of a CarMax dealership showing the storefront, logo signage, and parking lot with vehicles.
CarMax's Double Upgrade Could Signal a Bigger Turnaround
By Chris Markoch | October 20, 2026
Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0002 0.00 (0.00%)
As of 10/23/2026 09:30 AM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0004 0.00 (0.00%)
As of 10/23/2026

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas